This Friday, Sanofi announced a delay on the delivery of the vaccine against the coronavirus developed with the laboratoire britannique GSK, which should finally be ready for the end of 2021.
Summary Vaccine Sanofi Date of arrival of the vaccine Vaccine Sanofi in the world
[updated 11 December 2020 at 17h23] Huge disappointment for Sanofi and GSK. This Friday, the two laboratories have announced in a joint press release that their vaccine against the Covid-19, will not be finally ready for the first half of 2021, as they predicted. The first clinical trials have not been “up to expectations”, particularly in the elderly, said the president of GSK, Roger Connor, quoted in the press release. An inadequate immune response, which has therefore pushed the two labs to work out the formula of their antiviral. “We are naturally disappointed to announce this delay, but (…) we are confident and firmly committed to developing a safe and effective vaccine against the Covid-19”, for its part, said Thomas Triumph, the executive Vice president and head of Sanofi.
What is the effectiveness of the vaccine, Sanofi against the Covid ?
The percentage of efficacy of the vaccine of Sanofi Pasteur against the Covid-19 was not already known prior to this announcement. However, in their press release, Sanofi and GSK have elaborated on the reaction of the patients tested their vaccine. Among adults aged 18 to 49 years of age vaccinated, the results of the tests showed an immune response comparable to that of patients cured of an infection Covid-19. The weak immune response observed in more than 50 years would be, it is linked to a concentration of antigens is insufficient to allow the antiviral to be effective in all age groups.
When the vaccine Sanofi will it be accessible ?
While Sanofi and GSK hoped to be able to deliver their vaccine in the first half of 2021, the deadline is now extended to the end of the year 2021, “if the development plan is completed with success”. In their communiqué, the two laboratories indicate that a new phase of study is expected to begin in February 2021. Then, “if the data are positive, phase III of this study would commence in the second quarter of 2021”. Again, if the results of this last phase of trials are successful, an application for approval with the regulatory authorities could be filed in the second half of 2021, “which will have the effect of postponing the fourth quarter of 2021 the provision potential of the vaccine”, one can read in the press release.
country In which the vaccine Pfizer will it be available ?
